aTyr Pharma's efzofitimod misses primary endpoint in Phase 3 pulmonary sarcoidosis trial
ATYR•aTyr Pharma said its 48-week Phase 3 trial of efzofitimod in 268 patients with pulmonary sarcoidosis missed its primary goal of significantly reducing steroid use versus placebo, while patient-reported outcomes improved and lung function was maintained.
1. Trial results
The EFZO-FIT trial missed its primary goal of significantly reducing steroid use compared with placebo. Efzofitimod improved patient-reported outcomes, maintained lung function and was generally well tolerated. Study-related activities have begun for another global Phase 3 trial in pulmonary sarcoidosis.
